Mechanisms and clinical complications of hemolysis in sickle cell disease and thalassemia

Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Second Edition

Volumn , Issue , 2009, Pages 201-224

  Kato, Gregory J ^a   Gladwin, Mark T ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84932614805     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511596582.016     Document Type: Chapter

References (292)

1. Crosby WH. The metabolism of hemoglobin and bile pigment in hemolytic disease. Am JMed. 1955;18:112-122.
2. Franco RS, Yasin Z, Lohmann JM, et al. The survival characteristics of dense sickle cells. Blood. 2000;96:3610-3617.
3. Noguchi CT, Schechter AN. The intracellular polymerization of sickle hemoglobin and its relevance to sickle cell disease. Blood. 1981;58:1057-1068.
4. Nagel RL, Steinberg MH. Role of epistatic (modifier) genes in the modulation of the phenotypic diversity of sickle cell anemia. Pediatr PatholMolMed. 2001;20:123-136.
5. Eaton JW, Jacob HS, White JG. Membrane abnormalities of irreversibly sickled cells. Semin Hematol. 1979;16:52-64.
6. Kaul DK, Fabry ME, Nagel RL. Vaso-occlusion by sickle cells: evidence for selective trapping of dense red cells. Blood. 1986;68:1162-1166.
7. McCurdy PR, Sherman AS. Irreversibly sickled cells and red cell survival in sickle cell anemia: a study with both DF32P and 51CR. Am JMed. 1978;64:253-258.
8. Serjeant GR, Serjeant BE, Milner PF. The irreversibly sickled cell; a determinant of haemolysis in sickle cell anaemia. Br J Haematol. 1969;17:527-533.
9. Noguchi CT. Polymerization in erythrocytes containing S and non-S hemoglobins. Biophys J. 1984;45:1153-1158.
10. Brittenham GM, Schechter AN, Noguchi CT. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood. 1985;65:183-189.
11. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest. 1982;70:1253-1259.
12. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA. 2001;98:15215-15220.
13. Wood KC, Hebbel RP, Lefer DJ, Granger DN. Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radic BiolMed. 2006;40:1443-1453.
14. Hsu LL, Champion HC, Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood. In press.
15. Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood. 1991;77:214-237.
16. Shalev O, Hebbel RP. Catalysis of soluble hemoglobin oxidation by free iron on sickle red cell membranes. Blood. 1996;87:3948-3952.
17. Rice-Evans C, Omorphos SC, Baysal E. Sickle cell membranes and oxidative damage. Biochem J. 1986;237:265-269.
18. Rank BH, Carlsson J, Hebbel RP. Abnormal redox status of membrane-protein thiols in sickle erythrocytes. J Clin Invest. 1985;75:1531-1537.
19. Das SK, Nair RC. Superoxide dismutase, glutathione peroxidase, catalase and lipid peroxidation of normal and sickled erythrocytes. Br J Haematol. 1980;44:87-92.
20. Hebbel RP, Miller WJ. Phagocytosis of sickle erythrocytes: immunologic and oxidative determinants of hemolytic anemia. Blood. 1984;64:733-741.
21. Jain SK, Shohet SB. A novel phospholipid in irreversibly sickled cells: evidence for in vivo peroxidative membrane damage in sickle cell disease. Blood. 1984;63:362-367.
22. Platt OS, Falcone JF, Lux SE. Molecular defect in the sickle erythrocyte skeleton. Abnormal spectrin binding to sickle inside-our vesicles. J Clin Invest. 1985;75:266-271.
23. Schwartz RS, Rybicki AC, Heath RH, Lubin BH. Protein 4.1 in sickle erythrocytes. Evidence for oxidative damage. J Biol Chem. 1987;262:15666-15672.
24. Goodman SR. The irreversibly sickled cell: a perspective. Cell Mol Biol. 2004;50:53-58.
25. Lux SE, John KM, Karnovsky MJ. Irreversible deformation of the spectrin-actin lattice in irreversibly sickled cells. J Clin Invest. 1976;58:955-963.
26. Lachant NA, Davidson WD, Tanaka KR. Impaired pentose phosphate shunt function in sickle cell disease: a potential mechanism for increased Heinz body formation and membrane lipid peroxidation. Am J Hematol. 1983;15:1-13.
27. Schrader MC, Simplaceanu V, Ho C. Measurement of fluxes through the pentose phosphate pathway in erythrocytes from individuals with sickle cell anemia by carbon-13 nuclear magnetic resonance spectroscopy. Biochim Biophys Acta. 1993;1182:179-188.
28. Schrier SL. Pathophysiology of thalassemia. Curr Opin Hematol. 2002;9:123-126.
29. Amer J, Ghoti H, Rachmilewitz E, et al. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol. 2006;132:108-113.
30. Wetterstroem N, Brewer GJ, Warth JA, Mitchinson A, Near K. Relationship of glutathione levels and Heinz body formation to irreversibly sickled cells in sickle cell anemia. J Lab Clin Med. 1984;103:589-596.
31. Morris CR, Suh JH, Hagar W, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008;111:402-410.
32. Chang TL, Kakhniashvili DG, Goodman SR. Spectrin's E2/E3 ubiquitin conjugating/ligating activity is diminished in sickle cells. Am J Hematol. 2005;79:89-96.
33. Hsu YJ, Zimmer WE, Goodman SR. Erythrocyte spectrin's chimeric E2/E3 ubiquitin conjugating/ligating activity. Cell Mol Biol. 2005;51:187-193.
34. Ghatpande SS, Goodman SR. Ubiquitination of spectrin regulates the erythrocyte spectrin-protein-4.1-actin ternary complex dissociation: implications for the sickle cell membrane skeleton. CellMol Biol. 2004;50:67-74.
35. Gibson XA, Shartava A, McIntyre J, et al. The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in vitro. Blood. 1998;91:4373-4378.
36. Pace BS, Shartava A, Pack-Mabien A, et al. Effects of Nacetylcysteine on dense cell formation in sickle cell disease. Am J Hematol. 2003;73:26-32.
37. Jaja SI, Aigbe PE, Gbenebitse S, Temiye EO. Changes in erythrocytes following supplementation with alpha-tocopherol in children suffering from sickle cell anaemia. Niger Postgrad Med J. 2005;12:110-114.
38. Natta C, Machlin L. Plasma levels of tocopherol in sickle cell anemia subjects. Am J Clin Nutr. 1979;32:1359-1362.
39. Hasanato RM. Zinc and antioxidant vitamin deficiency in patients with severe sickle cell anemia. Ann Saudi Med. 2006;26:17-21.
40. Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with betathalassaemia or sickle cell disease. Br J Haematol. 2006;135: 254-263.
41. Gbenebitse S, Jaja SI, Kehinde MO. Effect of changes in plasma vitamin E level of vascular responses and lipid peroxidation in sickle cell anaemia subjects. Niger Postgrad Med J. 2005;12:81-84.
42. RayD, Deshmukh P, Goswami K, Garg N. Antioxidant vitamin levels in sickle cell disorders. Natl Med J India. 2007;20:11-13.
43. Middelkoop E, Lubin BH, Bevers EM, et al. Studies on sickled erythrocytes provide evidence that the asymmetric distribution of phosphatidylserine in the red cell membrane is maintained by both ATP-dependent translocation and interaction with membrane skeletal proteins. Biochim Biophys Acta. 1988;937:281-288.
44. Blumenfeld N, Zachowski A, Galacteros F, Beuzard Y, Devaux PF. Transmembrane mobility of phospholipids in sickle erythrocytes: effect of deoxygenation on diffusion and asymmetry. Blood. 1991;77:849-854.
45. Kuypers FA, de Jong K. The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol. 2004;50:147-158.
46. de Jong K, Geldwerth D, Kuypers FA. Oxidative damage does not alter membrane phospholipid asymmetry in human erythrocytes. Biochemistry. 1997;36:6768-6776.
47. Lang KS, Roll B, Myssina S, et al. Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency. Cell Physiol Biochem. 2002;12:365-372.
48. Kuypers FA, Yuan J, Lewis RA, et al. Membrane phospholipid asymmetry in human thalassemia. Blood. 1998;91:3044-3051.
49. Westerman MP, Diloy-Puray M, Streczyn M.Membrane components in the red cells of patients with sickle cell anemia. Relationship to cell aging and to irreversibility of sickling. Biochim Biophys Acta. 1979;557:149-155.
50. Franck PF, Bevers EM, Lubin BH, et al. Uncoupling of the membrane skeleton fromthe lipid bilayer. The cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickled cells. J Clin Invest. 1985;75:183-190.
51. Liu SC, Derick LH, Zhai S, Palek J.Uncoupling of the spectrinbased skeleton from the lipid bilayer in sickled red cells. Science. 1991;252:574-576.
52. Choe HR, Schlegel RA, Rubin E, Williamson P, Westerman MP. Alteration of red cell membrane organization in sickle cell anaemia. Br J Haematol. 1986;63:761-773.
53. Liu SC, Yi SJ, Mehta JR, et al. Red cell membrane remodeling in sickle cell anemia. Sequestration of membrane lipids and proteins in Heinz bodies. J Clin Invest. 1996;97:29-36.
54. Connor J, Pak CC, Schroit AJ. Exposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age, and clearance by mononuclear cells. J Biol Chem. 1994;269:2399-2404.
55. Closse C, chary-Prigent J, Boisseau MR. Phosphatidylserinerelated adhesion of human erythrocytes to vascular endothelium. Br J Haematol. 1999;107:300-302.
56. Setty BN, Kulkarni S, Stuart MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood. 2002;99:1564-1571.
57. Manodori AB, Barabino GA, Lubin BH, Kuypers FA. Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin. Blood. 2000;95:1293-1300.
58. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood. 1992;79:2154-2163.
59. Fabry ME, Benjamin L, Lawrence C, Nagel RL. An objective sign in painful crisis in sickle cell anemia: the concomitant reduction of high density red cells. Blood. 1984;64:559-563.
60. Allan D, Limbrick AR, Thomas P, Westerman MP. Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. Nature. 1982;295:612-613.
61. Padilla F, Bromberg PA, Jensen WN. The sickle-unsickle cycle: a cause of cell fragmentation leading to permanently deformed cells. Blood. 1973;41:653-660.
62. Platt OS. Exercise-induced hemolysis in sickle cell anemia: shear sensitivity and erythrocyte dehydration. Blood. 1982;59:1055-1060.
63. Diggs LW, Bibb J. The erythrocyte in sickle cell anemia: Morphology, size, hemoglobin content, fragility and sedimentation rate. JAMA. 1939;112:695-701.
64. Lange RD, Minnich V, Moore CV. Effects of oxygen tension and of pH of the sickling and mechanical fragility of erythrocytes from patients with sickle cell anemia and the sickle cell trait. J Lab ClinMed. 1951;37:789-802.
65. Shen SC, Fleming EM. Experimental and clinical observations on increased mechanical fragility of erythrocytes. Science. 1944;100:387-389.
66. Harris JW, Brewster HH, Ham TH, Castle WB. Studies on the destruction of red blood cells. X. The biophysics and biology of sickle-cell disease. AMA Arch InternMed. 1956;97:145-168.
67. Messmann R, Gannon S, Sarnaik S, Johnson RM. Mechanical properties of sickle cell membranes. Blood. 1990;75:1711-1717.
68. Liu SC, Zhai S, Palek J. Detection of hemin release during hemoglobin S denaturation. Blood. 1988;71:1755-1758.
69. Petz LD, Yam P, Wilkinson L, et al. Increased IgG molecules bound to the surface of red blood cells of patients with sickle cell anemia. Blood. 1984;64:301-304.
70. Bosman GJ. Erythrocyte aging in sickle cell disease. Cell Mol Biol. 2004;50:81-86.
71. Galili U, Clark MR, Shohet SB. Excessive binding of natural anti-alpha-galactosyl immunoglobin G to sickle erythrocytes may contribute to extravascular cell destruction. J Clin Invest. 1986;77:27-33.
72. Hebbel RP, Miller WJ. Unique promotion of erythrophagocytosis by malondialdehyde. Am J Hematol. 1988;29:222-225.
73. Low PS, Waugh SM, Zinke K, Drenckhahn D. The role of hemoglobin denaturation and band 3 clustering in red blood cell aging. Science. 1985;227:531-533.
74. Schluter K, Drenckhahn D. Co-clustering of denatured hemoglobin with band 3: its role in binding of autoantibodies against band 3 to abnormal and aged erythrocytes. Proc Natl Acad Sci USA. 1986;83:6137-6141.
75. Green GA, Kalra VK. Sickling-induced binding of immunoglobulin to sickle erythrocytes. Blood. 1988;71:636-639.
76. Test ST, Woolworth VS. Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation. Blood. 1994;83:842-852.
77. Liu C, Marshall P, Schreibman I, et al. Interaction between terminal complement proteins C5b-7 and anionic phospholipids. Blood. 1999;93:2297-2301.
78. Schroit AJ, Tanaka Y, Madsen J, Fidler IJ. The recognition of red blood cells by macrophages: role of phosphatidylserine and possible implications of membrane phospholipid asymmetry. Biol Cell. 1984;51:227-238.
79. Boas FE, Forman L, Beutler E. Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia. Proc Natl Acad Sci USA. 1998;95:3077-3081.
80. Kean LS, Brown LE, Nichols JW, et al. Comparison of mechanisms of anemia in mice with sickle cell disease and beta-thalassemia: peripheral destruction, ineffective erythropoiesis, and phospholipid scramblase-mediated phosphatidylserine exposure. Exp Hematol. 2002;30:394-402.
81. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flowcytometric measurement and clinical associations. Blood. 1996;88:1873-1880.
82. Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br J Haematol. 2002;118:893-898.
83. Borenstain-Ben Y, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol. 1993;44:63-65.
84. Wang RH, Phillips G Jr, Medof ME, Mold C. Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest. 1993;92:1326-1335.
85. Pearson HA, Spencer RP, Cornelius EA. Functional asplenia in sickle-cell anemia.NEngl J Med. 1969;281:923-926.
86. Powars DR, Pegelow CH. The spleen in sickle cell disease and thalassemia. Am J Pediatr Hematol Oncol. 1979;1:343-353.
87. Zimmerman SA, Ware RE. Palpable splenomegaly in children with haemoglobin SC disease: haematological and clinical manifestations. Clin Lab Haematol. 2000;22:145-150.
88. Wright JG, Hambleton IR, Thomas PW, et al. Postsplenectomy course in homozygous sickle cell disease. J Pediatr. 1999;134:304-309.
89. Al Salem AH, Qaisaruddin S, Nasserallah Z, al Dabbous, I, al Jam'a A. Splenectomy in patients with sickle-cell disease. Am J Surg. 1996;172:254-258.
90. Badaloo A, Emond A, Venugopal S, Serjeant G, Jackson AA. The effect of splenectomy on whole body protein turnover in homozygous sickle cell disease. Acta Paediatr Scand. 1991;80:103-105.
91. Robinson SH. Degradation of hemoglobin. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds. Hematology. New York:McGraw-Hill; 1983:388-395.
92. Schaer DJ, Alayash AI, Buehler PW. Gating the radical hemoglobin to macrophages: the anti-inflammatory role of CD163, a Scavenger Receptor. Antioxid Redox Signal. 2007;9:991-999.
93. Philippidis P, Mason JC, Evans BJ, et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocytemacrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res. 2004;94:119-126.
94. Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104:270-280.
95. Ryter SW, Otterbein LE, Morse D, Choi AM. Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance.Mol Cell Biochem. 2002;234-235:249-263.
96. Belcher JD, Mahaseth H, Welch TE, et al. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest. 2006;116:808-816.
97. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics. 2004;113:1776-1782.
98. Giblett ER, Coleman DH, Pirzio-Biroli G, et al. Erythrokinetics: quantitative measurements of red cell production and destruction in normal subjects and patients with anemia. Blood. 1956;11:291-309.
99. Nielsen MJ, Petersen SV, Jacobsen C, et al. Haptoglobinrelated protein is a high-affinity hemoglobin-binding plasma protein. Blood. 2006.
100. Removed in press.
101. Tizianello A, Pannacciulli I. The effect of splenomegaly on dilution curves of tagged erythrocytes and red blood cell volume. Coparative studies on normal, anaemic and splenomegalic patients. Acta Haematol. 1959;21:346-359.
102. Nomof N, Hopper J, Jr., Brown E, Scott K, Wennesland R. Simultaneous determinations of the total volume of red blood cells by use of carbon monoxide and chromium in healthy and diseased human subjects. J Clin Invest. 1954;33:1382-1387.
103. Huff RL, Feller DD. Relation of circulating red cell volume to body density and obesity. J Clin Invest. 1956;35:1-10.
104. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-666.
105. Lancaster JR Jr. A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide. 1997;1:18-30.
106. Wink DA, Mitchell JB. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic BiolMed. 1998;25:434-456.
107. Quyyumi AA, Dakak N, Andrews NP, et al.Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest. 1995;95:1747-1755.
108. Cannon RO, III, Schechter AN, Panza JA, et al. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest. 2001;108:279-287.
109. De CR, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
110. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653-1662.
111. Wong J, Fineman JR, Heymann MA. The role of endothelin and endothelin receptor subtypes in regulation of fetal pulmonary vascular tone. Pediatr Res. 1994;35:664-670.
112. Black SM, Mata-Greenwood E, Dettman RW, et al. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation. 2003;108:1646-1654.
113. Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med. 2003;348:1483-1485.
114. Doherty DH, Doyle MP, Curry SR, et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat Biotechnol. 1998;16:672-676.
115. Dou Y, Maillett DH, Eich RF, Olson JS.Myoglobin as a model system for designing heme protein based blood substitutes. Biophys Chem. 2002;98:127-148.
116. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383-1389.
117. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol. 2006;26:697-705.
118. Jeffers A, Gladwin MT, Kim-Shapiro DB. Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Radic BiolMed. 2006;41:1557-1565.
119. Coin JT, Olson JS. The rate of oxygen uptake by human red blood cells. J Biol Chem. 1979;254:1178-1190.
120. Liu X, Miller MJ, Joshi MS, et al. Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem. 1998;273:18709-18713.
121. Butler AR, Megson IL, Wright PG. Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim Biophys Acta. 1998;1425:168-176.
122. Liao JC, Hein TW, Vaughn MW, Huang KT, Kuo L. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci USA. 1999;96:8757-8761.
123. Vaughn MW, Kuo L, Liao JC. Effective diffusion distance of nitric oxide in the microcirculation. Am J Physiol. 1998;274:H1705-H1714.
124. Han TH, Hyduke DR, Vaughn MW, Fukuto JM, Liao JC. Nitric oxide reaction with red blood cells and hemoglobin under heterogeneous conditions. Proc Natl Acad Sci USA. 2002;99:7763-7768.
125. Huang KT, Han TH, Hyduke DR, et al. Modulation of nitric oxide bioavailability by erythrocytes. Proc Natl Acad Sci USA. 2001;98:11771-11776.
126. Vaughn MW, Huang KT, Kuo L, Liao JC. Erythrocytes possess an intrinsic barrier to nitric oxide consumption. J Biol Chem. 2000;275:2342-2348.
127. Savitsky JP, Doczi J, Black J, Arnold JD. A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther. 1978;23:73-80.
128. Carmichael FJ, Ali AC, Campbell JA, et al. A phase I study of oxidized raffinose cross-linked human hemoglobin. Crit Care Med. 2000;28:2283-2292.
129. Lamy ML, Daily EK, Brichant JF, et al. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group. Anesthesiology. 2000;92:646-656.
130. Viele MK, Weiskopf RB, Fisher D. Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. Anesthesiology. 1997;86:848-858.
131. Saxena R, Wijnhoud AD, Carton H, et al. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke. 1999;30:993-996.
132. Saxena R, Wijnhoud AD, Manin't Veld AJ, et al. Effect of diaspirin cross-linked hemoglobin on endothelin-1 and blood pressure in acute ischemic stroke in man. J Hypertens. 1998;16:1459-1465.
133. Przybelski RJ, Daily EK, Kisicki JC, et al. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit CareMed. 1996;24:1993-2000.
134. Reah G, Bodenham AR, Mallick A, Daily EK, Przybelski RJ. Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients. Crit Care Med. 1997;25:1480-1488.
135. Lamuraglia GM, O'Hara PJ, Baker WH, et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. J Vasc Surg. 2000;31:299-308.
136. Olson JS, Foley EW, Rogge C, et al. No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic BiolMed. 2004;36:685-697.
137. Murray JA, Ledlow A, Launspach J, et al. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology. 1995;109:1241-1248.
138. Olsen SB, Tang DB, Jackson MR, et al. Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model. Circulation. 1996;93:327-332.
139. Schafer A, Wiesmann F, Neubauer S, et al. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation. 2004;109:1819-1822.
140. Simionatto CS, Cabal R, Jones RL, Galbraith RA. Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers. Am JMed. 1988;85:538-540.
141. Villagra J, Shiva S, Hunter LA, et al. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007;110:2166-2172.
142. Sloan EP, Koenigsberg M, Brunett PH, et al. Post hoc mortality analysis of the efficacy trial of diaspirin cross-linked hemoglobin in the treatment of severe traumatic hemorrhagic shock. J Trauma. 2002;52:887-895.
143. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin crosslinked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA. 1999;282:1857-1864.
144. Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat Med. 2003;9:496-500.
145. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
146. Gladwin MT. Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J Clin Invest. 2006;116:2330-2332.
147. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107:271-278.
148. Eberhardt RT, McMahon L, Duffy SJ, et al. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol. 2003;74:104-111.
149. Nath KA, Shah V, Haggard JJ, et al. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol. 2000;279:R1949-R1955.
150. Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxidemediated vasodilation in transgenic sickle mouse. AmJ Physiol Heart Circ Physiol. 2000;278:H1799-H1806.
151. Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest. 2004;114:1136-1145.
152. Aslan M, Ryan TM, Townes TM, et al. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J Biol Chem. 2003;278:4194-4204.
153. Pritchard KA, Jr., Ou J, Ou Z, et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease. AmJ Physiol Lung CellMol Physiol. 2004;286:L705-L714.
154. Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J. 2005;19:989-991.
155. Removed in press.
156. Hsu LL, Champion HC, Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood. 2007;109:3088-3098.
157. Minneci PC, Deans KJ, Zhi H, et al. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest. 2005;115:3409-3417.
158. Siegler RL, Pysher TJ, Tesh VL, et al. Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS). Renal Fail. 2005;27:635-641.
159. Gramaglia I, Sobolewski P, Meays D, et al. Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. Nat Med. 2006;12:1417-1422.
160. Sobolewski P, Gramaglia I, Frangos J, Intaglietta M, van der Heyde HC. Nitric oxide bioavailability in malaria. Trends Parasitol. 2005;21:415-422.
161. Azizi E, Dror Y, Wallis K. Arginase activity in erythrocytes of healthy and ill children. Clin Chim Acta. 1970;28:391-396.
162. Morris CR, Morris SM, Jr., Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? AmJ Respir Crit CareMed. 2003;168:63-69.
163. Morris CR, Kato GJ, Poljakovic M, et al.Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension andMortality in Sickle Cell Disease. JAMA. 2005;294:81-90.
164. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. NEngl J Med. 2004;350:886-895.
165. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057-1058.
166. Radomski MW, Palmer RM, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol. 1987;92: 181-187.
167. Setty BN, Stuart MJ, Dampier C, Brodecki D, Allen JL. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet. 2003;362:1450-1455.
168. Quinn CT, Ahmad N. Clinical correlates of steady-state oxyhaemoglobin desaturation in children who have sickle cell disease. Br J Haematol. 2005;131:129-134.
169. Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78:139-145.
170. Chou R, DeLoughery TG. Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency. Am J Hematol. 2001;67:197-199.
171. Hayag-Barin JE, Smith RE, Tucker FC, Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol. 1998;57:82-84.
172. Aessopos A, Farmakis D, Deftereos S, et al. Cardiovascular effects of splenomegaly and splenectomy in betathalassemia. Ann Hematol. 2005;84:353-357.
173. Vichinsky EP. Pulmonary hypertension in sickle cell disease. NEngl J Med. 2004;350:857-859.
174. Westerman MP, Pizzey A, Hirschmann JV, et al. Plasma 'free' HB is related to red cell derived vesicle numbers in sickle cell anemia and thalassemia intermedia: implications for nitric oxide (NO) scavenging and pulmonary hypertension [abstract]. Blood. 2004;104:465a.
175. Kisanuki A, Kietthubthew S, Asada Y, et al. Intravenous injection of sonicated blood induces pulmonary microthromboembolism in rabbits with ligation of the splenic artery. Thromb Res. 1997;85:95-103.
176. Kietthubthew S, Kisanuki A, Asada Y, et al. Pulmonary microthromboembolism by injection of sonicated autologous blood in rabbits with splenic artery ligations. Southeast Asian J TropMed Public Health. 1997;28(Suppl 3):138-140.
177. Platt OS, Brambilla DJ, Rosse WF, et al.Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl JMed. 1994;330:1639-1644.
178. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337-338.
179. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411-420.
180. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood. 2005;106:3264-3267.
181. Kato GJ, McGowan VR, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension and death in patients with sickle cell disease. Blood. 2006;107:2279-2285.
182. Kato GJ, Hsieh M, Machado R, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol. 2006;81:503-510.
183. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37-47.
184. Collins FS, Orringer EP. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med. 1982;73:814-821.
185. Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore). 1988;67:66-76.
186. Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis JF. Pulmonary hypertension in sickle cell disease. Am J Cardiol. 1994;74:626-628.
187. Castro O. Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am. 1996;10:1289-1303.
188. Simmons BE, Santhanam V, Castaner A, et al. Sickle cell heart disease. Two-dimensional echo and Doppler ultrasonographic findings in the hearts of adult patients with sickle cell anemia. Arch InternMed. 1988;148:1526-1528.
189. Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol. 2002;33:1037-1043.
190. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101:1257-1261.
191. Boussaada R, Boubaker K, Mourali S, et al. [Pulmonary hypertension in sickle cell anemia. A case report]. Tunis Med. 2004;82(Suppl 1):180-184.
192. Ataga KI, Sood N, De GG, et al. Pulmonary hypertension in sickle cell disease. Am JMed. 2004;117:665-669.
193. Wu TJ, Tseng CD, Tseng YZ, et al. [A case of beta-thalassemia major with mediastinal hematopoietic tumor and pulmonary hypertension]. Taiwan Yi XueHui Za Zhi. 1986;85:315-320.
194. Aessopos A, Stamatelos G, Skoumas V, et al. Pulmonary hypertension and right heart failure in patients with betathalassemia intermedia. Chest. 1995;107:50-53.
195. Jootar P, Fucharoen S. Cardiac involvement in betathalassemia/hemoglobin E disease: clinical and hemodynamic findings. Southeast Asian J Trop Med Public Health. 1990;21:269-273.
196. Grisaru D, Rachmilewitz EA, Mosseri M, et al. Cardiopulmonary assessment in beta-thalassemia major. Chest. 1990; 98:1138-1142.
197. Finazzo M, Midiri M, D'Angelo P, et al. [The heart of the patient with beta thalassemia major. Study with magnetic resonance]. RadiolMed (Torino). 1998;96:462-465.
198. Derchi G, Fonti A, Forni GL, et al. Pulmonary hypertension in patients with thalassemia major. Am Heart J. 1999;138:384.
199. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411-3416.
200. Zakynthinos E, Vassilakopoulos T, Kaltsas P, et al. Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. Thorax. 2001;56:737-739.
201. Morris CR, Kuypers FA, Kato GJ, et al. Hemolysis-associated pulmonary hypertension in thalassemia. Ann NY Acad Sci. 2005;1054:481-485.
202. Uchida T, Miyake T, Matsuno M, et al. [Fatal pulmonary thromboembolism in a patient with paroxysmal nocturnal hemoglobinuria]. Rinsho Ketsueki. 1998;39:150-152.
203. Heller PG, Grinberg AR, Lencioni M, Molina MM, Roncoroni AJ. Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest. 1992;102:642-643.
204. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137:181-192.
205. Hayag-Barin JE, Smith RE, Tucker FC, Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol. 1998;57:82-84.
206. Verresen D, De Backer W, VanMeerbeeck J, et al. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? Eur Respir J. 1991;4:629-631.
207. Stewart GW, Amess JA, Eber SW, et al. Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol. 1996;93:303-310.
208. Jais X, Till SJ, Cynober T, et al. An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lungheart transplantation. Hemoglobin. 2003;27:139-147.
209. Murali B, Drain A, Seller D, Dunning J, Vuylsteke A. Pulmonary thromboendarterectomy in a case of hereditary stomatocytosis. Br J Anaesth. 2003;91:739-741.
210. Jardine DL, Laing AD. Delayed pulmonary hypertension following splenectomy for congenital spherocytosis. InternMed J. 2004;34:214-216.
211. Smedema JP, Louw VJ. Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis. Cardiovasc J S Afr. 2007;18:84-89.
212. Alvarez NR, Marin R. [Severe maternal complications associated with pre-eclampsia: an almost forgotten pathology?]. Nefrologia. 2001;21:565-573.
213. Stuard ID, Heusinkveld RS, Moss AJ. Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension.NEngl J Med. 1972;287:869-870.
214. McCarthy JT, Staats BA. Pulmonary hypertension, hemolytic anemia, and renal failure. A mitomycin-associated syndrome. Chest. 1986;89:608-611.
215. Jubelirer SJ. Primary pulmonary hypertension. Its association with microangiopathic hemolytic anemia and thrombocytopenia. Arch InternMed. 1991;151:1221-1223.
216. Suzuki H, Nakasato M, Sato S, et al. Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension. Tohoku J ExpMed. 1997;181:379-384.
217. Labrune P, Zittoun J, Duvaltier I, et al. Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Eur J Pediatr. 1999;158:734-739.
218. Fischer EG, Marek JM, Morris A, Nashelsky MB. Cholesterol granulomas of the lungs associated with microangiopathic hemolytic anemia and thrombocytopenia in pulmonary hypertension. Arch Pathol Lab Med. 2000;124:1813-1815.
219. Chou R, DeLoughery TG. Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency. Am J Hematol. 2001;67:197-199.
220. Zhang Y, Qui Y, Zhu J, Gao D. Pulmonary hypertension associated with autoimmune hemolytic anemia: a case report. Int J Cardiol. 2007;115:e1-e2.
221. Lode HN, Krings G, Schulze-Neick I, et al. Pulmonary hypertension in a case of Hb-Mainz hemolytic anemia. J Pediatr Hematol Oncol. 2007;29:173-177.
222. Huchzermeyer FW. Avian pulmonary hypertension syndrome. IV. Increased right ventricular mass in turkeys experimentally infected with Plasmodium durae. Onderstepoort J Vet Res. 1988;55:107-108.
223. Saissy JM, Rouvin B, Koulmann P. [Severe malaria in intensive care units in 2003].Med Trop (Mars.). 2003;63:258-266.
224. Ehrhardt S, Mockenhaupt FP, Anemana SD, et al. High levels of circulating cardiac proteins indicate cardiac impairment in African children with severe Plasmodium falciparum malaria.Microbes Infect. 2005;7:1204-1210.
225. Strauss E, Da Costa Gayotto LC, Antonelli R, et al. Systemic surgical shunts and splenomegaly as causes of haemolysis in portal hypertension in mansonic schistosomiasis. Evaluation through serum levels of haptoglobin, hemopexin and bilirubins. J Hepatol. 1986;2:340-350.
226. de CR, Herman P, Pugliese V, et al. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis-prospective study. Hepatogastroenterology. 2003;50:2028-2030.
227. Kyllonen K, Mattila T, Hartikainen M, Tala P. Mitral valve replacement with ball and tilting disc valve prosthesis. A clinical and haemodynamic study. Scand J Thorac Cardiovasc Surg. 1976;10:15-20.
228. Iwaki H, Kuraoka S, Tatebe S. [Hemolytic anemia due to aortic valve regurgitation after mitral valve replacement]. Kyobu Geka. 2003;56:124-128.
229. Chukwuemeka AO, Turtle MR, Trivedi UH, Venn GE, Chambers DJ. A clinical evaluation of platelet function, haemolysis and oxygen transfer during cardiopulmonary bypass comparing the Quantum HF-6700 to the HF-5700 hollow fibre membrane oxygenator. Perfusion. 2000;15:479-484.
230. Pierangeli A, Masieri V, Bruzzi F, et al.Haemolysis during cardiopulmonary bypass: how to reduce the free haemoglobin by managing the suctioned blood separately. Perfusion. 2001;16:519-524.
231. Gerrah R, Shargal Y, Elami A. Impaired oxygenation and increased hemolysis after cardiopulmonary bypass in patients with glucose-6-phosphate dehydrogenase deficiency. Ann Thorac Surg. 2003;76:523-527.
232. Takami Y, Makinouchi K, Nakazawa T, et al. Hemolytic characteristics of a pivot bearing supported Gyro centrifugal pump (C1E3) simulating various clinical applications. Artif Organs. 1996;20:1042-1049.
233. Jackson N, Franklin IM, Hughes MA. Recurrent priapism following splenectomy for thalassaemia intermedia. Br J Surg. 1986;73:678.
234. Rao KR, Patel AR. Priapism and thalassaemia intermedia. Br J Surg. 1986;73:1048.
235. Macchia P, Massei F, Nardi M, et al. Thalassemia intermedia and recurrent priapism following splenectomy. Haematologica. 1990;75:486-487.
236. Dore F, Bonfigli S, Pardini S, Pirozzi F, Longinotti M. Priapism in thalassemia intermedia. Haematologica. 1991;76: 523.
237. Andrieu V, Dumonceau O, Grange MJ. Priapism in a patient with unstable hemoglobin: hemoglobin Koln. Am J Hematol. 2003;74:73-74.
238. Gyan E, Darre S, Jude B, et al. Acute priapism in a patient with unstable hemoglobin Perth and Factor V Leiden under effective oral anticoagulant therapy. Hematol J. 2001;2:210-211.
239. Thuret I, Bardakdjian J, Badens C, et al. Priapism following splenectomy in an unstable hemoglobin: hemoglobin Olmsted beta 141 (H19) Leu->Arg. Am J Hematol. 1996;51:133-136.
240. Goulding FJ. Priapism caused by glucose phosphate isomerase deficiency. J Urol. 1976;116:819-820.
241. Edney MT, Schned AR, Cendron M, Chaffee S, Ellsworth PI. Priapism in a 15-year-old boy with congenital dyserythropoietic anemia type II (hereditary erythroblastic multinuclearity with positive acidified serum lysis test). J Urol. 2002;167:309-310.
242. Nolan VG, Baldwin C, Ma Q, et al. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol. 2005;128:266-272.
243. Christakis J, Vavatsi N, Hassapopoulou H, et al. Comparison of homozygous sickle cell disease in northern Greece and Jamaica. Lancet. 1990;335:637-640.
244. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA. 2005;102:1661-1666.
245. Sawhney H, Weedon J, Gillette P, Solomon W, Braverman A. Predilection of hemolytic anemia-associated leg ulcers for the medial malleolus. Vasa. 2002;31:191-193.
246. Fucharoen S, Ketvichit P, Pootrakul P, et al. Clinical manifestation of beta-thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol. 2000;22:552-557.
247. Eckman JR. Leg ulcers in sickle cell disease. Hematol Oncol Clin North Am. 1996;10:1333-1344.
248. Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood. 1989;74:1403-1408.
249. Levy LA. Foot and ankle ulcers associated with hematologic disorders. Clin Podiatry. 1985;2:631-637.
250. Gimmon Z, Wexler MR, Rachmilewitz EA. Juvenile leg ulceration in beta-thalassemia major and intermedia. Plast Reconstr Surg. 1982;69:320-325.
251. Daneshmend TK, Peachey RD. Leg ulcers in alphathalassaemia (haemoglobin H disease). Br J Dermatol. 1978; 98:233-235.
252. Stevens DM, Shupack JL, Javid J, Silber R. Ulcers of the leg in thalassemia. Arch Dermatol. 1977;113:1558-1560.
253. Leverkus M, Schwaaf A, Brocker EB, Runger TM. Recurrent hemolysis-associated pseudoerysipelas of the lower legs in a patient with congenital spherocytosis. J Am Acad Dermatol. 2004;51:1019-1023.
254. Giraldi S, Abbage KT, Marinoni LP, et al. Leg ulcer in hereditary spherocytosis. Pediatr Dermatol. 2003;20:427-428.
255. Lawrence P, Aronson I, Saxe N, Jacobs P. Leg ulcers in hereditary spherocytosis. Clin Exp Dermatol. 1991;16:28-30.
256. Vanscheidt W, Leder O, Vanscheidt E, et al. Leg ulcers in a patient with spherocytosis: a clinicopathological report. Dermatologica. 1990;181:56-59.
257. Rivera-Biaschoechea ZA. Hereditary spherocytosis with leg ulcer and unaffected parents or siblings. Report of one case. Bol AsocMed P R. 1964;56:109-114.
258. Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol. 2006;133:570-578.
259. Kato GJ, Hsieh M, Machado R, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol. 2006;81:503-510.
260. Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am JMed. 1997;102:171-177.
261. Buchanan GR, DeBaun MR, Quinn CT, Steinberg MH. Sickle cell disease. Hematology Am Soc Hematol Educ Program. 200:435-447.
262. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 2005;129:465-481.
263. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288-294.
264. Lezcano NE, Odo N, Kutlar A, Brambilla D, Adams RJ. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke. 2006;37:1424-1426.
265. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. NEngl J Med. 2004;350:886-895.
266. Graham JK, Mosunjac M, Hanzlick RL, Mosunjac M. Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review. AmJ ForensicMed Pathol. 2007;28:168-172.
267. Aessopos A, Stamatelos G, Skoumas V, et al. Pulmonary hypertension and right heart failure in patients with betathalassemia intermedia. Chest. 1995;107:50-53.
268. Wu KH, Chang JS, Su BH, Peng CT. Tricuspid regurgitation in patients with beta-thalassemia major. Ann Hematol. 2004;83:779-783.
269. Singer ST, Kuypers FA, Styles L, et al. Pulmonary hypertension in thalassemia: Association with platelet activation and hypercoagulable state. Am J Hematol. 2006;81:670-675.
270. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127:1523-1530.
271. Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol. 2004;73:359-366.
272. Ataga KI, Sood N, De GG, et al. Pulmonary hypertension in sickle cell disease. Am JMed. 2004;117:665-669.
273. De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes. Am J Hematol. 2008;83:19-25.
274. Ataga KI, Sood N, De GG, et al. Pulmonary hypertension in sickle cell disease. Am JMed. 2004;117:665-669.
275. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134:109-115.
276. Taylor JG, Woods GM, Machado R, Kato GJ, Gladwin MT. Severe pulmonary hypertension in an adolescent with sickle cell disease. Am J Hematol. 2007;83:71-72.
277. Kato GJ, Onyekwere OC, Gladwin MT. Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr Hematol Oncol. 2007;24:159-170.
278. Young EM, Zilberman MV, Du W, Sarnaik SA. Pulmonary hypertension in pediatric patients with sickle cell disease: a retrospective study. Blood. 2004;104:23b.
279. Onyekwere OC, Campbell AD, Teshome M, et al. Pulmonary hypertension in sickle cell disease children and adolescents. Pediatr Cardiol. 2007;24:159-170.
280. Ambrusko SJ, Gunawardena S, Sakara A, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer. 2006;47:907-913.
281. Liem RI, Young LT, Thompson AA. Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension. Haematologica. 2007;92:1549-1552.
282. Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Br J Haematol. In press.
283. Sedrak A, Rao SP, Miller ST, Hekmet V, Rao M. Pulmonary hypertension in children and adolescents with sickle cell disease. Blood. 2006;108:21b-22b.
284. Deem S, Kim SS, Min JH, et al. Pulmonary vascular effects of red blood cells containing S-nitrosated hemoglobin. Am J Physiol Heart Circ Physiol. 2004;287:H2561-H2568.
285. Sachdev V, Machado RF, Shizukuda Y, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J AmColl Cardiol. 2007;49:472-479.
286. Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007;175:1272-1279.
287. Machado RF, Mack AK, Martyr S, et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol. 2007;136:319-325.
288. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol. 1999;33:1662-1666.
289. Little JA, McGowan VR, Kato GJ, et al. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006;91:1076-1083.
290. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005;130:445-453.
291. Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol. 2005;129:449-464.
292. Lin EE, Rodgers GP, Gladwin MT. Hemolytic anemiaassociated pulmonary hypertension in sickle cell disease. Curr Hematol Rep. 2005;4:117-125.